TY - JOUR
T1 - Caging the dragon
T2 - Research approach to COVID-19-related thrombosis
AU - Kruip, Marieke J H A
AU - Cannegieter, Suzanne C
AU - Ten Cate, Hugo
AU - van Gorp, Eric C M
AU - Juffermans, Nicole P
AU - Klok, Frederikus A
AU - Maas, Coen
AU - Vonk-Noordegraaf, Anton
N1 - Funding Information:
The DCTC has initiated a comprehensive research program to answer many of the current questions on the pathophysiology and best treatment of COVID‐19–associated thrombotic complications. The main objective of DCTC’s research is to understand and prevent VTE in people with COVID‐19, and to optimize acute treatment and long‐term health of people with COVID‐19 who are diagnosed with VTE. This objective concerns the overall Dutch population but also important subgroups, including age categories, sex, and ethnic groups. The subobjectives of the five involved work packages (WPs) are summarized in Table 1 , and the integration of the WPs is illustrated in Figure 1 . The foundation and strength of this research is the enormous amount of collected data of people with COVID‐19 combined with locally collected and biobanked samples and materials. In addition, the consortium combines wide‐ranging expertise on topics in any way related to the current project. The research program was funded by grants of the Netherlands Thrombosis Foundation and the Netherlands Organization for Health Research and Development.
Publisher Copyright:
© 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
PY - 2021/2
Y1 - 2021/2
N2 - The incidence of venous thrombosis, mostly pulmonary embolism (PE), ranging from local immunothrombosis to central emboli, but also deep vein thrombosis (DVT) in people with coronavirus disease 2019 (COVID-19) is reported to be remarkably high. The relevance of better understanding, predicting, treating, and preventing COVID-19-associated venous thrombosis meets broad support, as can be concluded from the high number of research, review, and guideline papers that have been published on this topic. The Dutch COVID & Thrombosis Coalition (DCTC) is a multidisciplinary team involving a large number of Dutch experts in the broad area of venous thrombosis and hemostasis research, combined with experts on virology, critically ill patients, pulmonary diseases, and community medicine, across all university hospitals and many community hospitals in the Netherlands. Within the consortium, clinical data of at least 5000 admitted COVID-19-infected individuals are available, including substantial collections of biobanked materials in an estimated 3000 people. In addition to considerable experience in preclinical and clinical thrombosis research, the consortium embeds virology-hemostasis research models within unique biosafety facilities to address fundamental questions on the interaction of virus with epithelial and vascular cells, in relation to the coagulation and inflammatory system. The DCTC has initiated a comprehensive research program to answer many of the current questions on the pathophysiology and best anticoagulant treatment of COVID-19-associated thrombotic complications. The research program was funded by grants of the Netherlands Thrombosis Foundation and the Netherlands Organization for Health Research and Development. Here, we summarize the design and main aims of the research program.
AB - The incidence of venous thrombosis, mostly pulmonary embolism (PE), ranging from local immunothrombosis to central emboli, but also deep vein thrombosis (DVT) in people with coronavirus disease 2019 (COVID-19) is reported to be remarkably high. The relevance of better understanding, predicting, treating, and preventing COVID-19-associated venous thrombosis meets broad support, as can be concluded from the high number of research, review, and guideline papers that have been published on this topic. The Dutch COVID & Thrombosis Coalition (DCTC) is a multidisciplinary team involving a large number of Dutch experts in the broad area of venous thrombosis and hemostasis research, combined with experts on virology, critically ill patients, pulmonary diseases, and community medicine, across all university hospitals and many community hospitals in the Netherlands. Within the consortium, clinical data of at least 5000 admitted COVID-19-infected individuals are available, including substantial collections of biobanked materials in an estimated 3000 people. In addition to considerable experience in preclinical and clinical thrombosis research, the consortium embeds virology-hemostasis research models within unique biosafety facilities to address fundamental questions on the interaction of virus with epithelial and vascular cells, in relation to the coagulation and inflammatory system. The DCTC has initiated a comprehensive research program to answer many of the current questions on the pathophysiology and best anticoagulant treatment of COVID-19-associated thrombotic complications. The research program was funded by grants of the Netherlands Thrombosis Foundation and the Netherlands Organization for Health Research and Development. Here, we summarize the design and main aims of the research program.
KW - anticoagulants
KW - COVID-19
KW - pulmonary embolism
KW - severe acute respiratory syndrome coronavirus 2
KW - thrombosis
KW - venous thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85102210647&partnerID=8YFLogxK
U2 - 10.1002/rth2.12470
DO - 10.1002/rth2.12470
M3 - Article
C2 - 33733026
SN - 2475-0379
VL - 5
SP - 278
EP - 290
JO - Research and practice in thrombosis and haemostasis
JF - Research and practice in thrombosis and haemostasis
IS - 2
ER -